Geneuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsy… Read more
Geneuro SA (GNRO) - Total Liabilities
Latest total liabilities as of December 2023: €20.14 Million EUR
Based on the latest financial reports, Geneuro SA (GNRO) has total liabilities worth €20.14 Million EUR as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Geneuro SA - Total Liabilities Trend (2012–2023)
This chart illustrates how Geneuro SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Geneuro SA Competitors by Total Liabilities
The table below lists competitors of Geneuro SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JM SMUCKER
MU:JM2
|
Germany | €12.39 Billion |
|
China Teletech Holding Inc
PINK:CNCT
|
USA | $71.33K |
|
CHARLES SCHWAB
BE:SWG
|
Germany | €405.72 Billion |
|
Network Media Group Inc
OTCQB:NETWF
|
USA | $9.42 Million |
|
Standard Life PLC
LSE:SDLF
|
UK | GBX308.18 Billion |
Liability Composition Analysis (2012–2023)
This chart breaks down Geneuro SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Geneuro SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Geneuro SA (2012–2023)
The table below shows the annual total liabilities of Geneuro SA from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €20.14 Million | +101.26% |
| 2022-12-31 | €10.01 Million | +30.05% |
| 2021-12-31 | €7.69 Million | +54.00% |
| 2020-12-31 | €5.00 Million | -65.80% |
| 2019-12-31 | €14.61 Million | +171811.08% |
| 2018-12-31 | €8.50K | -50.92% |
| 2017-12-31 | €17.31K | -9.42% |
| 2016-12-31 | €19.11K | +0.23% |
| 2015-12-31 | €19.07K | -99.32% |
| 2014-12-31 | €2.82 Million | +89.33% |
| 2013-12-31 | €1.49 Million | -71.43% |
| 2012-12-31 | €5.21 Million | -- |